Shield Therapeutics plc (SHIEF)
OTCMKTS · Delayed Price · Currency is USD
0.1491
0.00 (0.00%)
At close: Feb 10, 2026
Shield Therapeutics Company Description
Shield Therapeutics plc, a commercial stage specialty pharmaceutical company, focuses on development and commercialization of clinical-stage pharmaceuticals to treat unmet medical needs.
Its lead product is Accrufer/Feraccru, a non-salt based oral therapy for adults to treat the iron deficiency with or without anemia.
Shield Therapeutics plc was incorporated in 2008 and is based in Gateshead, the United Kingdom.
Shield Therapeutics plc
| Country | United Kingdom |
| Founded | 2008 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 63 |
| CEO | Anders Lundstrom |
Contact Details
Address: Northern Design Centre Gateshead, NE8 3DF United Kingdom | |
| Phone | 44 1915 118 500 |
| Website | shieldtherapeutics.com |
Stock Details
| Ticker Symbol | SHIEF |
| Exchange | OTCMKTS |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| ISIN Number | GB00BYV81293 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Anders Lundstrom | Chief Executive Officer and Executive Director |
| Dr. Christian Schweiger M.D., Ph.D. | Co-Founder and Non Executive Director |
| Santosh Shanbhag | Chief Financial Officer |
| Lucy Kate Huntington-Bailey | General Counsel, Chief Compliance Officer and Company Secretary |
| Suzanne Wood | Group Human Resources Director |
| Carol Akinola | Head of Pharmacovigilance and Medical Information |
| Andrew Hurley | Chief Commercial Officer |
| Kate Armanetti | Senior Director of People and Culture |